OBJECTIVE The aim of this study was to determine whether premeal pulmonary delivery of rapid-acting, dry-powder insulin (Exubera) plus Ultralente could provide glycemic control comparable to a conventional insulin regimen in type 1 diabetes. RESEARCH DESIGN AND METHODS Three hundred thirty-five subjects were randomly assigned to receive either premeal inhaled insulin plus bedtime Ultralente o...

OBJECTIVES To review the clinical effectiveness and cost-effectiveness of a new technology, the inhaled insulin, Exubera (Pfizer and Sanofi-Aventis, in collaboration with Nektar Therapeutics), a short-acting insulin. DATA SOURCES Electronic databases were searched up to November 2005. REVIEW METHODS A systematic literature review was conducted and economic modelling carried out. An industry...

Inhalational insulin was withdrawn from the market due to its potential to produce airway hyper-reactivity and bronchoconstriction. So the present study was designed to explore the acute effects of insulin on airway reactivity of guinea pigs and protective effects of salbutamol and ipratropium against insulin induced airway hyper-responsiveness on isolated tracheal smooth muscle of guinea pig. ...

OBJECTIVE To compare the dose-response relationship following inhalation of regular insulin delivered via the Aerodose insulin inhaler with that following subcutaneously injected regular insulin in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Twenty-four patients with type 2 diabetes (21 nonsmoking men, aged 36-80 years) each received two of three doses of 80, 160, or 240 units ...

Targeted glycemic control in patients with type 1 and type 2 diabetes is grossly inadequate, despite data demonstrating reduced microvascular and macrovascular diabetic complications with intensive treatment. A significant proportion of individuals with poorly-controlled type 2 diabetes are resistant to initiating treatment with insulin. Several decades-long search for alternative forms of insu...

OBJECTIVE We sought to compare and evaluate the impact of inhaled versus injected insulin on potential mediators of patient acceptance of insulin therapy while maintaining comparable A1C levels. RESEARCH DESIGN AND METHODS During a noninferiority efficacy trial conducted in 40 centers in the U.S., we surveyed treatment satisfaction, quality of life, and adherence barriers at weeks -4, -1, 6, ...

10.1586/14750708.3.3.339 © 2 Delivering insulin via the inhalation route is an exciting concept. Recent progress in inhalation technology has enabled development of inhaled insulin-delivery systems. Exubera® (inhaled human insulin; INH; insulin, human [rDNA origin] Inhalation Powder) is one of several inhaled insulins being developed, and is the first inhaled insulin to obtain regulatory approv...